News about Drug Discovery & Development

US FDA Delays Two Drug Reviews Under New Priority Voucher Program

The U.S. Food and Drug Administration (FDA) has delayed the review of two medicines selected under its recently launched Commissioner’s National Priority Voucher Program, after regulators raised concerns related to safety and clinical effectiveness.

Drug Discovery & Development | 16/01/2026 | By Darshana |  406

J&J's Tecvayli Cuts Death Risk in Phase III Multiple Myeloma Study

Phase III MajesTEC-9 shows Tecvayli significantly improves survival, reducing progression or death risk by 71 percent versus standard care in relapsed multiple myeloma.

Drug Discovery & Development | 15/01/2026 | By News Bureau |  148

European Commission Approves Teizeild to Delay Onset of Type 1 Diabetes

Teizeild (teplizumab) becomes the first disease-modifying therapy approved in the EU to delay progression to stage III type 1 diabetes in eligible adults and children aged eight and above.

Drug Discovery & Development | 13/01/2026 | By News Bureau |  266

Phanes Therapeutics Presents First Clinical Data for Spevatamig in Metastatic Pancreatic Cancer

Early data from the Twinpeak study presented at ASCO GI 2026 show encouraging safety and efficacy of spevatamig combined with chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma.

Drug Discovery & Development | 12/01/2026 | By News Bureau |  276

Nona Biosciences, Link Cell Therapies Partner to Advance Next-Gen CAR-T Antibody Discovery

The multi-target collaboration will combine Nona Biosciences’ fully human HCAb Harbour Mice and NonaCarFx platforms with Link Cell Therapies’ cell therapy expertise to develop novel CAR-T candidates for solid and hematologic cancers.

Drug Discovery & Development | 12/01/2026 | By News Bureau |  207

Pierre Fabre, Iktos Partner on AI-Driven Oncology Drug Discovery Collaboration

The partnership between Pierre Fabre and Iktos integrates generative AI and automated chemistry to accelerate small-molecule cancer drug development.

Drug Discovery & Development | 09/01/2026 | By News Bureau |  277

Mercy Joins REACH Study to Evaluate GRAIL Galleri Test in Medicare Population

The three year clinical study will assess real-world impact of multi-cancer early detection testing among up to 50,000 Medicare beneficiaries.

Drug Discovery & Development | 09/01/2026 | By News Bureau |  191

Newron Strengthens Evenamide IP Portfolio with New European Patent Approval

Newron Pharmaceuticals S.p.A., a biopharmaceutical company focused on developing innovative therapies for disorders of the central and peripheral nervous system, announced that the European Patent Office (EPO) has granted an additional patent covering its lead drug candidate, evenamide.

Drug Discovery & Development | 08/01/2026 | By Darshana |  191

Variant Bio partners with Boehringer Ingelheim for Research on Kidney Disease

The multi-year collaboration with Boehringer Ingelheim will leverage Variant Bio’s AI-powered Inference platform to identify novel kidney disease drug targets, with financial terms including upfront, licence and milestone payments that could exceed USD 120 million.

Drug Discovery & Development | 08/01/2026 | By News Bureau |  225

Inimmune Begins Phase 2 Trial of INI-2004 for Allergic Rhinitis

The randomised, placebo-controlled allergen chamber study will evaluate the safety and efficacy of Inimmune’s immunotherapy candidate INI-2004 in patients exposed to controlled ragweed allergens.

Drug Discovery & Development | 08/01/2026 | By News Bureau |  251